drugset / Trial / NCT02463591

Reversal of Dabigatran With Prothrombin Complex Concentrate

NCT02463591

RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to investigate whether Prothrombin Complex Concentrate (PCC) is effective in reversing the anticoagulant effect of Dabigatran, as assessed by two modified skin-bleeding tests.

Timeline

Start
2015-01
Primary completion
2016-07
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Prothrombin Complex Concentrate Protein / enzyme biologic 50 iu/kg Intravenous

Indications

No indication recorded.